CTI BioPharma to Present at The JMP Securities Hematology Summit on Tuesday, Dec. 15

Rhea-AI Summary

CTI BioPharma Corp. (NASDAQ: CTIC) announced a corporate overview presentation at the JMP Securities Hematology Summit on Tuesday, Dec. 15, at 3:00 p.m. EST. The event will be conducted virtually and can be accessed via a live webcast from the Investors section of the company's website.

CTI BioPharma focuses on developing targeted therapies for blood-related cancers, with its lead product candidate, pacritinib, currently in late-stage development for myelofibrosis and recently developed for severe COVID-19 treatment.

SEATTLE, Dec. 8, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at The JMP Securities Hematology Summit at 3:00 p.m. EST. The conference will be held in a virtual meeting format.

Presentation details:

Event: The JMP Securities Hematology Summit
Date: Tuesday, Dec. 15
Time: 3:00 p.m. EST

The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

About CTI BioPharma Corp.
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

CTI BioPharma Investor Contacts:
Maeve Conneighton/Maghan Meyers
+212-600-1902
cti@argotpartners.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-jmp-securities-hematology-summit-on-tuesday-dec-15-301187816.html

SOURCE CTI BioPharma Corp.

FAQ

What is the date and time of CTI BioPharma's presentation at the JMP Securities Hematology Summit?

CTI BioPharma will present at the JMP Securities Hematology Summit on Tuesday, Dec. 15, 2020, at 3:00 p.m. EST.

How can I access the CTI BioPharma presentation at the JMP Securities Hematology Summit?

The presentation will be webcast live and available for replay on the Investors section of CTI BioPharma's website.

What is pacritinib and its significance for CTI BioPharma?

Pacritinib is CTI BioPharma's lead product candidate aimed at treating myelofibrosis and recently developed for severe COVID-19 patients.

Where is CTI BioPharma headquartered?

CTI BioPharma is headquartered in Seattle, Washington.